CD8A and neoplasm: Flow cytometry analysis confirmed the higher abundance of Treg on tumor-targeted therapy (figure 2G, online supplemental figure 2d), and furthermore, revealed the highest Treg/CD8+ T cell ratio in the resistant phase (figure 2H).